Aims-To determine the sensitivity of commercially available diagnostic assays for Chlamydia trachomatis using a simple method. Methods-Nine commercial assays and an "in-house" polymerase chain reaction (PCR) were evaluated using serial dilutions of a laboratory grown H serovarfour of them using a laboratory grown E serovar. Seven of the assays were fiurther tested using dilutions of several cervical samples known to contain chlamydiae. Results-The most sensitive assays were the MicroTrak direct fluorescent antibody (DFA) test (Syva) and the PCR which detected C trachomatis at a 10-dilution of the H serovar, while the two least sensitive, Clearview (Unipath) and TestPack (Abbott), were positive only at 10-4 and 10-3 dilutions, respectively. A range of enzyme immunoassays (EIAs) and a nucleic acid hybridisation test were of intermediate sensitivity. The results with serovar E were consistent with these. When clinical samples were examined, the DFA test detected C trachomatis in dilutions at least 10-fold greater than any other assay. Conclusions-The range of sensitivity of diagnostic assays determined by the laboratory dilution procedure is very wide. Sensitivity assessed in this way, however, reflects the ability of the assays to detect C trachomatis in large scale clinical trials. The dilution procedure, which is simple to undertake, could therefore be applied by any laboratory before a new diagnostic method is considered for routine use.
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Methods

C TRACHOMATIS SEROVARS
Serovar H (UW4) and serovar E (DK20) of C trachomatis were cultured in cycloheximide treated McCoy cell monolayers,' resuspended in 0-2 M sucrose phosphate buffer (2SP), containing 10% fetal calf serum, and stored in aliquots in liquid nitrogen.
CLINICAL SAMPLES
Cervical swab samples were obtained from women attending the genitourinary medicine clinic at St Mary's Hospital, Paddington. Swabs for some assays (IDEIA; PACE 2) were placed directly into transport tubes provided for the assay, and those for others were replaced in dry tubes and transported to the laboratory within six hours.
DIAGNOSTIC KITS TESTED
Seven commercially available EIAs, a DNA probe (PACE 2), and a direct fluorescent antibody (DFA) test were evaluated. These diagnostic kits comprised: (1) In assays 1 and 2 the whole volume of the initial sample (1 ml) and dilutions in extraction buffer were required for the test, so that none was available for centrifugation; in assay 8 chlamydial elementary bodies were disrupted to release ribosomal RNA, so none would remain intact in the deposit for DFA staining. In these three assays, therefore, double volumes of the initial sample and of all the dilutions were made, one half being used in each assay and the centrifuged deposit from 
*log,0; U = undiluted; N = negative.
the other half being stained by the DFA method. Assays 2, 4, 5, 6, 8 , and 9 were tested up to four times using different aliquots of the same stock chlamydial pool. Serovar E was used to test assays 4, 7, 8, and 9 in the same manner.
Use of clinical samples Swabs for the IDEIA and PACE 2 assays arrived at the laboratory in the respective transport medium. The recommended volume of transport extraction buffer was added to the dry swabs for the Syva EIA, Celisa, Wellcozyme and Clearview tests and the swabs were vortexed in the medium, in each case according to the manufacturer's instructions. The resulting suspension was regarded as the original, undiluted sample and 10-fold dilutions (10-l to 104) of it were made in 0 9 ml volumes of extraction buffer. These dilutions, and the original sample, were then tested in all the assays, according to the manufacturer's instructions. As before, the remainder of each sample, or dilution, was centrifuged and the deposit stained by the DFA method. The highest dilution found to contain elementary bodies was recorded. It should come as no surprise that assays in which, in competent hands, a single elementary body may be detected, should be extremely sensitive. The lack of sensitivity of the other assays examined reflects their inherent inability to detect the LPS or ribosomal RNA extracted from small numbers of elementary bodies. This is a problem which may be compounded, in some cases, by only a small portion (100-200 ,l) of the original 1 ml clinical sample being tested. This aspect should be addressed by the manufacturers. Perhaps it should be borne in mind that when culture was the only means of detecting C trachomatis elementary bodies, the whole sample was tested and, indeed, passaged before a negative result was reported. The use of the whole sample in the Clearview assay may account in part for its better, although in our view inadequate, performance when clinical samples were tested.
Results
DETECTION OF C TRACHOMATIS SEROVARS
The comparison of assays in large scale clinical trials may be valuable, but the results should be viewed with caution. It is possible to make any assay appear sensitive by comparing it with a suboptimal test, or to conceal a lack of specificity by excluding cultured specimens contaminated by those organisms which react non-specifically in the assay under investigation. In short, almost any result may ensue, albeit inadvertently. By using dilutions of laboratory grown C trachomatis elementary bodies in a new assay and in one already in use, any laboratory will have a rapid, reproducible, and objective means of comparing their relative sensitivities. Furthermore, comparing the results of examining specimens by a new assay with those obtained on the same specimens with the MT DFA test or PCR will reveal the absolute sensitivity of the new method. Some will claim that such comparisons are unrealistic, but only when these are undertaken and the results are reported will the manufacturers of diagnostic tests improve their products to an acceptable level. 
